(floo DARE a been)
- Fludarabine Monophosphate
- Fludarabine Phosphate
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Intravenous, as phosphate:
Generic: 50 mg/2 mL (2 mL)
Solution, Intravenous, as phosphate [preservative free]:
Generic: 50 mg/2 mL (2 mL)
Solution Reconstituted, Intravenous, as phosphate:
Fludara: 50 mg (1 ea [DSC])
Generic: 50 mg (1 ea)
Solution Reconstituted, Intravenous, as phosphate [preservative free]:
Generic: 50 mg (1 ea)
Brand Names: U.S.
- Fludara [DSC]
- Antineoplastic Agent, Antimetabolite
- Antineoplastic Agent, Antimetabolite (Purine Analog)
Fludarabine inhibits DNA synthesis by inhibition of DNA polymerase and ribonucleotide reductase; also inhibits DNA primase and DNA ligase I
Vss: 11 to 96 L/m2 (Johnson 2000)
IV: Fludarabine phosphate is rapidly dephosphorylated in the plasma to 2-fluoro-ara-A (active metabolite), which subsequently enters tumor cells and is phosphorylated by deoxycytidine kinase to the active triphosphate derivative (2-fluoro-ara-ATP)
Urine (primarily) (Johnson 2000)
Time to Peak
Oral: 1 to 2 hours
2-fluoro-ara-A: Adults: ~20 hours
2-fluoro-ara-A: ~19% to 29%
Special Populations: Renal Function Impairment
Total body clearance of the principal metabolite correlates with creatinine clearance (CrCl). Mean body clearance is 124 mL/minute for patients with moderate renal impairment and 71 mL/minute for patients with severe renal impairment. In 2 patients with a median CrCl of 22 mL/minute/m2, clearance was reduced by 56%.
Use: Labeled Indications
Chronic lymphocytic leukemia (refractory or progressive): Treatment of B-cell chronic lymphocytic leukemia (CLL) in adults who have not responded to or have progressed during treatment with at least one standard regimen containing an alkylating agent.
Canadian labeling: Second-line treatment of chronic lymphocytic leukemia (Oral and IV); second-line treatment of low-grade, refractory non-Hodgkin lymphoma (IV only)
Treatment of non-Hodgkin lymphomas (NHL); acute myeloid leukemia (AML), either refractory or in poor risk patients; relapsed acute lymphocytic leukemia (ALL) or AML in pediatric patients; Waldenström macroglobulinemia (WM); reduced-intensity conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (generally administered in combination with busulfan or cyclophosphamide and antithymocyte globulin or lymphocyte immune globulin, or in combination with melphalan and alemtuzumab)
There are no contraindications listed in the manufacturer’s US labeling.
Canadian labeling: Hypersensitivity to fludarabine or any component of the formulation; severe renal impairment (CrCl <30 mL/minute; oral and IV); decompensated hemolytic anemia; concurrent use with pentostatin
Chronic lymphocytic leukemia (CLL), refractory or progressive:
IV: 25 mg/m2 once daily for 5 consecutive days every 28 days; continue for at least 3 additional cycles after maximal response is achieved
Oral (Canadian product; not available in US): 40 mg/m2 once daily for 5 consecutive days every 28 days
CLL combination regimens (off-label dosing): IV:
FC regimen: 30 mg/m2/day for 3 days every 28 days for 6 cycles (in combination with cyclophosphamide) (Eichhorst 2006) or 20 mg/m2/day for 5 days every 28 days for 6 cycles (in combination with cyclophosphamide) (Flinn 2007)
FCR regimen: 25 mg/m2/day for 3 days every 28 days for 6 cycles (in combination with cyclophosphamide and rituximab) (Keating 2005; Robak 2010; Wierda 2005)
FR regimen: 25 mg/m2/day for 5 days every 28 days for 6 cycles (in combination with rituximab) (Byrd 2003)
OFAR regimen: 30 mg/m2/day for 2 days every 28 days for 6 cycles (in combination with oxaliplatin, cytarabine, and rituximab) (Tsimberidou 2008)
Acute myeloid leukemia, newly diagnosed (off-label use): IV: 30 mg/m2/day for 5 days (in combination with cytarabine ± G-CSF ± idarubicin (FA, FLAG, or FLAG-IDA regimens), followed by consolidation therapy (Borthakur 2008; Burnett 2013)
Acute myeloid leukemia, refractory or high/poor-risk patients (off-label use): IV: 30 mg/m2/day for 5 days (in combination with cytarabine and filgrastim [FLAG regimen]), may repeat once for partial remission (Montillo 1998) or 30 mg/m2/day for 5 days for 1 or 2 cycles (in combination with cytarabine, idarubicin, and filgrastim FLAG-IDA regimen]) (Virchis 2004)
Hematopoietic stem cell transplant (allogeneic) myeloablative conditioning regimen (off-label use): IV: 40 mg/m2/day for 4 days (in combination with busulfan) beginning 6 days prior to transplantation (Rambaldi 2015).
Hematopoietic stem cell transplant (allogeneic) reduced-intensity conditioning regimen (off-label use): IV: 30 mg/m2/day for 5 days (in combination with melphalan and alemtuzumab) prior to transplant (Tauro 2005) or 30 mg/m2/day for 6 days beginning 10 days prior to transplant or 30 mg/m2/day for 5 days beginning 6 days prior to transplant (in combination with busulfan with or without antithymocyte globulin) (Schetelig 2003)
Hematopoietic stem cell transplant (allogeneic) nonmyeloablative conditioning regimen (off-label use): IV: 30 mg/m2/day for 3 doses beginning 5 days prior to transplant (in combination with cyclophosphamide and rituximab) (Khouri 2008) or 30 mg/m2/day for 3 doses beginning 4 days prior to transplant (in combination with total body irradiation) (Hegenbart 2006; Rezvani 2008)
Non-Hodgkin lymphomas (off-label use): IV:
Follicular lymphoma, relapsed/refractory
FCR regimen: 25 mg/m2/day for 3 days every 21 days for 4 cycles (in combination with cyclophosphamide and rituximab) (Sacchi 2007)
FCMR regimen: 25 mg/m2/day for 3 days every 28 days for 4 cycles (in combination with cyclophosphamide, mitoxantrone, and rituximab) (Forstpointner 2004; Forstpointner 2006)
FNDR regimen: 25 mg/m2/day for 3 days every 28 days for up to 8 cycles (in combination with mitoxantrone, dexamethasone, and rituximab) (McLaughlin 2000)
FR regimen: 25 mg/m2/day for 5 days every 28 days for 6 cycles (in combination with rituximab) (Czuczman 2005)
Mantle cell lymphoma, relapsed or refractory:
FC regimen: 20 mg/m2/day for 4 to 5 days or 25 mg/m2/day for 3 to 5 days (in combination with cyclophosphamide) (Cohen 2001)
Waldenstrom macroglobulinemia (off-label use): IV: 25 mg/m2/day for 5 days every 28 days (Foran 1999) or 25 mg/m2/day for 5 days every 28 days for 6 cycles (in combination with rituximab) (Treon 2009)
Refer to adult dosing.
Acute lymphocytic leukemia, relapsed (off-label use): IV: 10.5 mg/m2 bolus over 15 minutes followed by a continuous infusion of 30.5 mg/m2/day for 48 hours in combination with cytarabine (Avramis 1998). Additional studies may be necessary to further define the role of fludarabine in the condition.
Acute myeloid leukemia, newly diagnosed (off-label use): IV: 10.5 mg/m2 bolus infusion followed by a continuous infusion of 30.5 mg/m2/day for 48 hours (in combination with cytarabine and idarubicin) during consolidation phase of treatment (Lange 2008)
Acute myeloid leukemia, relapsed (off-label use): IV: 10.5 mg/m2 bolus over 15 minutes followed by a continuous infusion of 30.5 mg/m2/day for 48 hours in combination with cytarabine (Avramis 1998). Additional studies may be necessary to further define the role of fludarabine in the condition.
Hematopoietic stem cell transplant (allogeneic), reduced-intensity conditioning regimen (off-label use): IV: 30 mg/m2 once daily for 6 doses beginning 7 to 10 days prior to transplant (in combination with busulfan and antithymocyte globulin [rabbit]) (Pulsipher 2009)
Dosing: Renal Impairment
US labeling: Adults: CLL: IV:
CrCl ≥80 mL/minute: No dosage adjustment necessary (administer the usual dose of 25 mg/m2).
CrCl 50 to 79 mL/minute: Reduce dose to 20 mg/m2.
CrCl 30 to 49 mL/minute: Reduce dose to 15 mg/m2.
CrCl <30 mL/minute: Use is not recommended.
Canadian labeling: CLL (Oral, IV), NHL (IV):
CrCl 30 to 70 mL/minute: Reduce dose by up to 50%.
CrCl <30 mL/minute: Use is contraindicated.
The following adjustments have also been used: Aronoff 2007: IV:
CrCl 10 to 50 mL/minute: Reduce dose to 75% of usual dose.
CrCl <10 mL/minute: Reduce dose to 50% of usual dose.
Hemodialysis: Reduce dose to 50% of usual dose; administer after dialysis
Continuous ambulatory peritoneal dialysis (CAPD): Reduce dose to 50% of usual dose.
Continuous renal replacement therapy (CRRT): Reduce dose to 75% of usual dose.
CrCl 30 to 50 mL/minute: Reduce dose to 80% of usual dose.
CrCl <30 mL/minute: Use is not recommended.
Hemodialysis: Reduce dose to 25% of usual dose
Continuous ambulatory peritoneal dialysis (CAPD): Use is not recommended.
Continuous renal replacement therapy (CRRT): Reduce dose to 80% of usual dose.
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer's labeling.
Dosing: Adjustment for Toxicity
Hematologic or nonhematologic toxicity (other than neurotoxicity): Consider treatment delay or dosage reduction.
Hemolysis: Discontinue treatment.
Neurotoxicity: Consider treatment delay or discontinuation.
American Society of Clinical Oncology (ASCO) Guidelines for appropriate chemotherapy dosing in obese adults with cancer (Note: Excludes leukemias and HSCT dosing): Utilize patient’s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).
American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity: Utilize actual body weight (full weight) for calculation of body surface area in fludarabine dosing for hematopoietic stem cell transplant conditioning regimens in adults (Bubalo 2014).
Reconstitute lyophilized powder with 2 mL SWFI to a concentration of 25 mg/mL.
Dilute for infusion in 100 to 125 mL D5W or NS.
IV: The manufacturer recommends administering over ~30 minutes (for the treatment of CLL). Continuous infusions and IV bolus over 15 minutes have been used for some off-label protocols (refer to individual studies for infusion rate details).
Oral: Tablet [Canadian product] may be administered with or without food; should be swallowed whole with water; do not chew, break, or crush.
See Trissel’s IV Compatibility Database
IV: Store intact vials under refrigeration or at room temperature, as specified according to each manufacturer’s labeling. Protect from light. Reconstituted solution or vials of the solution for injection that have been punctured (in use) should be used within 8 hours.
Tablet [Canadian product]: Store at 15°C to 30°C (59°F to 86°F); should be kept within packaging until use.
BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Monitor therapy
Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. Monitor therapy
Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Avoid combination
Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. Monitor therapy
Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Avoid combination
Echinacea: May diminish the therapeutic effect of Immunosuppressants. Consider therapy modification
Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections). Consider therapy modification
Imatinib: May diminish the myelosuppressive effect of Fludarabine. Imatinib may decrease the serum concentration of Fludarabine. More specifically, imatinib may decrease the formation of fludarabine active metabolite F-ara-ATP Management: Due to the risk for impaired fludarabine response, consider discontinuing imatinib therapy at least 5 days prior to initiating fludarabine conditioning therapy in CML patients undergoing HSCT. Consider therapy modification
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Consider therapy modification
Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim. Consider therapy modification
Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Avoid combination
Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. Consider therapy modification
Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy. Consider therapy modification
Pentostatin: May enhance the adverse/toxic effect of Fludarabine. Pulmonary toxicity is of specific concern. Fludarabine may enhance the adverse/toxic effect of Pentostatin. Avoid combination
Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination
Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapy
Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants. Consider therapy modification
Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. Monitor therapy
Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination
Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib. Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants. Avoid combination
Trastuzumab: May enhance the neutropenic effect of Immunosuppressants. Monitor therapy
Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Consider therapy modification
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants. Avoid combination
Frequency not always defined.
Cardiovascular: Edema (8% to 19%)
Central nervous system: Fatigue (10% to 38%), neurological signs and symptoms (doses >96 mg/m2 /day for 5 to 7 days: 36%; doses <125 mg/m2/cycle: <1%; characterized by cortical blindness, coma, and paralysis; symptom onset may be delayed for 3 to 4 weeks), pain (20% to 22%), chills (11% to 19%), paresthesia (4% to 12%)
Dermatologic: Skin rash (15%), diaphoresis (1% to 13%)
Gastrointestinal: Nausea and vomiting (31% to 36%), anorexia (7% to 34%), diarrhea (13% to 15%), gastrointestinal hemorrhage (3% to 13%)
Genitourinary: Urinary tract infection (2% to 15%)
Hematologic & oncologic: Anemia (60%), neutropenia (grade 4: 59%; nadir: ~13 days), thrombocytopenia (55%; nadir: ~16 days), bone marrow depression (nadir: 10 to 14 days; recovery: 5 to 7 weeks; dose-limiting toxicity)
Infection: Infection (33% to 44%)
Neuromuscular & skeletal: Weakness (9% to 65%), myalgia (4% to 16%)
Ophthalmic: Visual disturbance (3% to 15%)
Respiratory: Cough (10% to 44%), pneumonia (16% to 22%), dyspnea (9% to 22%), upper respiratory tract infection (2% to 16%)
Miscellaneous: Fever (60% to 69%)
1% to 10%:
Cardiovascular: Angina pectoris (≤6%), cardiac arrhythmia (≤3%), cardiac failure (≤3%), cerebrovascular accident (≤3%), myocardial infarction (≤3%), supraventricular tachycardia (≤3%), deep vein thrombosis (1% to 3%), phlebitis (1% to 3%), aneurysm (≤1%), transient ischemic attacks (≤1%)
Central nervous system: Malaise (6% to 8%), headache (≤3%), sleep disorder (1% to 3%), cerebellar syndrome (≤1%), depression (≤1%), difficulty thinking (≤1%)
Dermatologic: Alopecia (≤3%), pruritus (1% to 3%), seborrhea (≤1%)
Endocrine & metabolic: Hyperglycemia (1% to 6%), dehydration (≤1%)
Gastrointestinal: Stomatitis (≤9%), cholelithiasis (≤3%), esophagitis (≤3%), constipation (1% to 3%), mucositis (≤2%), dysphagia (≤1%)
Genitourinary: Dysuria (3% to 4%), urinary hesitancy (≤3%), hematuria (2% to 3%), proteinuria (≤1%)
Hematologic & oncologic: Hemorrhage (≤1%), tumor lysis syndrome (≤1%)
Hepatic: Abnormal hepatic function tests (1% to 3%), hepatic failure (≤1%)
Hypersensitivity: Anaphylaxis (≤1%)
Neuromuscular & skeletal: Osteoporosis (≤2%), arthralgia (≤1%)
Otic: Hearing loss (2% to 6%)
Renal: Renal failure (≤1%), renal function test abnormality (≤1%)
Respiratory: Pharyngitis (≤9%), hypersensitivity pneumonitis (≤6%), hemoptysis (1% to 6%), sinusitis (≤5%), bronchitis (≤1%), epistaxis (≤1%), hypoxia (≤1%)
<1% (Limited to important or life-threatening): Acquired blood coagulation disorder, acute myelocytic leukemia (usually associated with prior or concurrent treatment with other anticancer agents), adult respiratory distress syndrome, autoimmune hemolytic anemia, autoimmune thrombocytopenia, blindness, bone marrow aplasia (trilineage), bone marrow depression (trilineage), cerebral hemorrhage, coma, Epstein-Barr-associated lymphoproliferative disorder, erythema multiforme, Evan’s syndrome, hemorrhagic cystitis, hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, immune thrombocytopenia (autoimmune), interstitial pulmonary infiltrate, malignant neoplasm of skin (new-onset or exacerbation), metabolic acidosis, myelodysplastic syndrome (usually associated with prior or concurrent treatment with other anticancer agents), myelofibrosis, opportunistic infection, optic neuritis, optic neuropathy, pancytopenia, pemphigus, pericardial effusion, peripheral neuropathy, pneumonitis, progressive multifocal leukoencephalopathy (PML), pulmonary fibrosis, pulmonary hemorrhage, reactivation of latent Epstein-Barr virus, reactivation of latent herpes zoster, respiratory distress, respiratory failure, seizure, Stevens-Johnson syndrome, toxic epidermal necrolysis, urate crystalluria, wrist-drop
Concerns related to adverse effects:
• Autoimmune effects: [US Boxed Warning]: Life-threatening (and sometimes fatal) autoimmune effects, including hemolytic anemia, autoimmune thrombocytopenia/thrombocytopenic purpura (ITP), Evans syndrome, and acquired hemophilia have occurred; evaluate and monitor closely for hemolysis. This has occurred in patients with and without a history of autoimmune hemolytic anemia or a positive Coombs test, and who may or may not be in remission from their disease. Corticosteroids may or may not effectively control the hemolytic episodes. Discontinue fludarabine if hemolysis occurs. The hemolytic effects recurred in most patients when rechallenged with fludarabine.
• Bone marrow suppression: [US Boxed Warning]: Severe bone marrow suppression (anemia, thrombocytopenia, and neutropenia) may occur; may be cumulative. The median time to nadir was 13 days (range: 3 to 25 days) for granulocytes and 16 days (range: 2 to 32 days) for platelets. Severe myelosuppression (trilineage bone marrow hypoplasia/aplasia) has been reported (rare) with a duration of significant cytopenias ranging from 2 months to 1 year. First-line combination therapy is associated with prolonged cytopenias, with anemia lasting up to 7 months, neutropenia up to 9 months, and thrombocytopenia up to 10 months; increased age is predictive for prolonged cytopenias (Gill 2010). Monitor patients with bone marrow impairment closely for excess toxicity; may require dosage reductions.
• Infection: Serious and sometimes fatal infections, including opportunistic infections have been reported with fludarabine. Prophylactic anti-infectives should be considered for patients with an increased risk for developing opportunistic infections. Use with caution in patients with documented infection, fever, immunodeficiency, or with a history of opportunistic infection.
• Neurotoxicity: [US Boxed Warning]: Higher than recommended doses (up to 96 mg/m2/day for 5 to 7 days) are associated with severe neurologic toxicity (delayed blindness, coma, death); similar neurotoxicity (agitation, coma, confusion, seizure) has been reported (rare) with standard CLL doses (25 mg/m2/day for 5 days). Symptoms of neurotoxicity due to high doses appeared from 21 to 60 days following the last fludarabine dose, although neurotoxicity has been reported as early as 7 days and up to 225 days. Although administration of up to 15 courses of treatment have been used, the possible neurotoxic effects of chronic administration are unknown. Fatigue, weakness and visual disturbances may occur; caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).
• Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML) (usually fatal) due to JC virus has been reported; most cases were in patients who had received prior and/or other concurrent chemotherapy. Onset may be a few weeks or may be delayed up to 1 year. Evaluate any neurological change promptly.
• Reproductive effects: Fludarabine may damage testicular tissue and spermatozoa.
• Transfusion-associated graft-versus-host disease: Graft-versus-host disease (GVHD) has been observed following transfusion of non-irradiated blood in patients treated with fludarabine; fatal outcome has been observed. Patients receiving fludarabine should only receive irradiated blood products due to the potential for transfusion-related GVHD.
• Tumor lysis syndrome: May cause tumor lysis syndrome; risk is increased in patients with large tumor burden prior to treatment. Hydration and prophylactic antihyperuricemic therapy should be considered in patients at risk for tumor lysis syndrome.
• Renal impairment: Use with caution in patients with renal impairment; clearance of the primary metabolite 2-fluoro-ara-A is decreased in patients with renal impairment. Dosage reductions are recommended (monitor closely for excessive toxicity) in patients with creatinine clearance between 30 and 79 mL/minute; use is not recommended if CrCl <30 mL/minute.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Pentostatin: [US Boxed Warning]: The use of fludarabine in combination with pentostatin (deoxycoformycin) for the treatment of refractory chronic lymphocytic leukemia has resulted in an unacceptably high incidence of fatal pulmonary toxicity. The use of fludarabine in combination with pentostatin is not recommended.
• Elderly: Monitor closely for excessive toxicity; may require reduced doses.
• Experienced physician: [US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.
• Live vaccines: Avoid vaccination with live vaccines during and after fludarabine treatment.
CBC with differential, platelet count, AST, ALT, serum creatinine, serum albumin, uric acid; monitor for signs of infection, neurotoxicity, and tumor lysis syndrome
Pregnancy Risk Factor
Adverse events were observed in animal reproduction studies. Based on the mechanism of action, fludarabine may cause fetal harm if administered during pregnancy. Effective contraception should be used to avoid pregnancy during and after treatment for women and men with female partners of reproductive potential.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience chills, sweating a lot, or muscle pain. Have patient report immediately to prescriber signs of progressive multifocal leukoencephalopathy (confusion, depression, trouble with memory, behavioral changes, change in strength on one side, trouble speaking, change in balance, vision changes), signs of infection, signs of bleeding (vomiting blood or vomit that looks like coffee grounds; coughing up blood; blood in the urine; black, red, or tarry stools; bleeding from the gums; abnormal vaginal bleeding; bruises without a reason or that get bigger; or any bleeding that is very bad or that will not stop), signs of progressive multifocal leukoencephalopathy (confusion, depression, trouble with memory, behavioral changes, change in strength on one side, trouble speaking, change in balance, vision changes), signs of tumor lysis syndrome (fast heartbeat or abnormal heartbeat; any passing out; trouble passing urine; muscle weakness or cramps; upset stomach, throwing up, loose stools or not able to eat; or feel sluggish), signs of a severe pulmonary disorder (lung or breathing problems like trouble breathing, shortness of breath, or a cough that is new or worse), shortness of breath, angina, mood changes, illogical thinking, seizures, severe nausea, vomiting, severe diarrhea, cough that will not go away, urinary retention, loss of strength and energy, jaundice, skin growths, burning or numbness feeling, lack of appetite, vision changes, vision loss, swelling of arms or legs, or signs of Stevens-Johnson syndrome/toxic epidermal necrolysis (red, swollen, blistered, or peeling skin [with or without fever]; red or irritated eyes; or sores in mouth, throat, nose, or eyes) (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
More about fludarabine
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 1 Review – Add your own review/rating